This study is testing a new medicine called PF-08634404 to see if it helps adults with metastatic colorectal cancer. Metastatic means the cancer has spread to other parts of the body. If you join, you will be randomly placed in one of two groups. Group A will get the new medicine combined with regular chemotherapy. Group B will get a different approved medicine, called Bevacizumab, with chemotherapy. Both medicines are given through an intravenous (IV) infusion, which means directly into a vein. You won't know which treatment you're getting.

• The study lasts about 33 months and includes regular visits for treatment and health checks.
• After stopping treatment, there's a final check-up 30 to 37 days later.
• Follow-up checks will happen every 12 weeks by phone, in person, or by reviewing health records.

To join, you must be at least 18, have cancer that's spread, and be healthy enough for treatment. You can't be pregnant or have certain medical conditions. This study helps researchers learn if the new medicine works better together with chemotherapy.